Bevacizumab for Treating EGFR Mutation-Positive Non-Small-Cell Lung Cancer (terminated appraisal) (TA436)

Elotuzumab for Previously Treated Multiple Myeloma (terminated appraisal) (TA434)

Everolimus for Advanced Renal Cell Carcinoma after Previous Treatment (TA432)

Ibrutinib for Previously Treated Chronic Lymphocytic Leukaemia and Untreated Chronic Lymphocytic Leukaemia with 17p Deletion or TP53 Mutation (TA429)

Pomalidomide for Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib (TA427)

Pembrolizumab for Treating PD-L1-Positive Non-Small-Cell Lung Cancer After Chemotherapy (TA428)

Dasatinib, Nilotinib and Imatinib for Untreated Chronic Myeloid Leukaemia (TA426)

Dasatinib, Nilotinib and High-Dose Imatinib for Treating Imatinib-Resistant or Intolerant Chronic Myeloid Leukaemia (TA425)

Pertuzumab for the Neoadjuvant Treatment of HER2-Positive Breast Cancer (TA424)

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After 2 or More Chemotherapy Regimens (TA423)

Load More